Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

April 18, 2017; 88 (16 Supplement) April 25, 2017

Effect of adjunctive perampanel on myoclonic and absence seizures: post-hoc analysis of data from the Extension Phase of a Phase III study in patients with idiopathic generalized epilepsy (IGE) (P3.236)

Christian Brandt, Robert Wechsler, Terence J O’Brien, Antonio Laurenza, Anna Patten, Francesco Bibbiani, Betsy Williams
First published April 17, 2017,
Christian Brandt
1Bethel Epilepsy Center Bielefeld Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Wechsler
2Idaho Comprehensive Epilepsy Center Boise ID United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Terence J O’Brien
3Royal Melbourne Hospital, University of Melbourne Melbourne Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antonio Laurenza
4Eisai Inc. Woodcliffe Lake NJ United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Patten
5Eisai Ltd. Hatfield United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francesco Bibbiani
4Eisai Inc. Woodcliffe Lake NJ United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Betsy Williams
4Eisai Inc. Woodcliffe Lake NJ United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Effect of adjunctive perampanel on myoclonic and absence seizures: post-hoc analysis of data from the Extension Phase of a Phase III study in patients with idiopathic generalized epilepsy (IGE) (P3.236)
Christian Brandt, Robert Wechsler, Terence J O’Brien, Antonio Laurenza, Anna Patten, Francesco Bibbiani, Betsy Williams
Neurology Apr 2017, 88 (16 Supplement) P3.236;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: To assess the effects of adjunctive perampanel on myoclonic and absence seizures in IGE.

Background: Perampanel is a selective, non-competitive AMPA receptor antagonist, approved for adjunctive treatment of focal seizures, with or without secondarily generalized seizures, and for primary generalized tonic-clonic (PGTC) seizures in patients with epilepsy aged ≥12 years. Approval for PGTC seizures was based on the placebo-controlled Phase III Study 332 in patients with PGTC seizures and IGE. Since some AEDs can aggravate seizures in IGE, a post-hoc analysis was performed to assess myoclonic and absence seizure outcomes in the Extension Phase of Study 332.

Design/Methods: Study 332 methodology has been published (French et al. Neurology 2015;85:950–957). Patients completing the Double-blind study could receive perampanel during an Extension Phase, including a 6-week blinded Conversion Period (dose optimized to maximum of 12 mg/day) and up to 136 weeks’ unblinded Maintenance. For this post-hoc analysis, the following endpoints were assessed for absence and myoclonic seizures across the Extension Phase: median percent changes in seizure frequency per 28 days, and proportions of patients achieving reductions in seizure frequency of ≥50% (50% responder rate) or 100% (seizure freedom rate).

Results: Of 138 patients entering the Extension Phase, 76 experienced myoclonic (n=46) and/or absence (n=52) seizures at Pre-perampanel Baseline. At Weeks 40–52 of perampanel treatment, data were available for 65 of these patients (myoclonic, n=40; absence, n=43). At this time window, median percent changes in seizure frequency were −100.0% for both seizure types, 50% responder rates were 82.5% for myoclonic and 76.7% for absence seizures, and seizure freedom rates were 57.5% for myoclonic and 55.8% for absence seizures.

Conclusions: In this small, post-hoc analysis, median percent changes in frequency did not indicate any overall worsening of myoclonic or absence seizures in patients with IGE.

Study Supported by: Eisai Inc.

Disclosure: Dr. Brandt has received personal compensation for activities with Eisai, UCB and Desitin as a consultant, speaker and advisory board member. Dr. Wechsler has received personal compensation for activities with Cyberonics, Eisai, Sunovion, Marinus, and Lundbeck. Dr. O'Brien has received personal compensation for activities with UCB Pharma and Eisai Inc. Dr. O'Brien has received research support from Eisai Inc., UCB Pharma, Sanofi-Aventis Pharmaceuticals, Inc., SciGen, Marinus and UPS. Dr. Laurenza has received personal compensation for activities with Eisai Inc. as an employee. Dr. Patten has received personal compensation for activities with Eisa Ltd as an employee. Dr. Bibbiani has received personal compensation for activities with Eisai Inc. as an employee. Dr. Williams has received personal compensation for activities with Eisai, Inc.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 96 (4)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise